Use of fluoroquinolones for empirical management of febrile neutropenia in pediatric cancer patients

Pediatric Infectious Disease Journal

Volumn 16, Issue 1, 1997, Pages 140-146

  Freifeld, Alison ^a   Pizzo, Philip ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cancer; empiric treatment; febrile neutropenia; Fluoroquinolones; pediatric

Indexed keywords

CEFOPERAZONE; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADOLESCENT; ANTIBIOTIC THERAPY; CHILD; CHILDHOOD CANCER; CONFERENCE PAPER; DRUG EFFICACY; DRUG FORMULATION; HUMAN; HUMAN TISSUE; INFECTION RISK; NEUTROPENIA; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

ADMINISTRATION, ORAL; ANTI-INFECTIVE AGENTS; CHILD; CIPROFLOXACIN; FEVER OF UNKNOWN ORIGIN; HUMANS; NEOPLASMS; NEUTROPENIA; RISK;

EID: 0031040769     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199701000-00039     Document Type: Conference Paper

References (29)

1. Bodey G, Buckley M, Sathe Y, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40.
2. Schimpff S, Young V, Greene W, et al. Origin of infection in acute nonlymphocytic leukemia: significance of hospital acquisition of potential pathogens. Ann Intern Med 1972;77: 707-14.
3. Pizzo P, Robichaud K, Wesley R, et al. Fever in the pediatric and young adult patient with cancer: a prospective study of 1001 episodes. Medicine 1982;61:153-65.
4. Schimpff S. Overview of empiric antibiotic therapy for the febrile neutropenic patient. Rev Infect Dis 1985;7(Suppl 4): S734-40.
5. Love L, Schimpff S, Schiffer C, et al. Improved prognosis for granulocytopenic patients with Gram-negative bacteremia. Am J Med 1980;68:1-10.
6. Pizzo P, Robichaud K, Gill F, et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101-11.
7. Pizzo P, Hathorn J, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986;315:552-8.
8. Hughes W, Armstrong D, Bodey G, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161:381-96.
9. Freifeld A, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995;13: 165-76.
10. Sanders JW, Powe NR, Moore RD. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis. J Infect Dis 1991;164:907-16.
11. Wood M, Newland A. Intravenous ciprofloxacin in the treatment of infection in immunocompromised patients. J Antimicrob Chemother 1986;18:175-8.
12. Rolston K, Haron E, Cunningham C, et al. Intravenous ciprofloxacin for infections in cancer patients. Am J Med 1989;87(Suppl 5A):261S-265S.
13. Meunier F, Zinner H, Gaya H, et al. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. Antimicrob Agents Chemother 1991;35:873-8.
14. Classen D, Burke J, Ford C, et al. Streptococcus mitis sepsis in bone marrow transplant patients receiving oral antimicrobial prophylaxis. Am J Med 1990;89:441-6.
15. Kotilainen P, Nikoskelainen J, Huovinen P. Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin. J Infect Dis 1990;161:41-4.
16. Oppenheim BA, Hartley JW, Lee W, et al. Outbreak of coagulase negative staphylococcus highly resistant to ciprofloxacin in a leukaemia unit. Br Med J 1989;299:294-7.
17. Elting L, Bodey G, Keefe B. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1992;14:1201-7.
18. Chan C, Oppenheim B, Anderson H, et al. Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients. Antimicrob Agents Chemother 1989;33:87-91.
19. Kelsey S, Wood M, Shaw E, et al. Intravenous ciprofloxacin as empirical treatment of febrile neutropenic patients. Am J Med 1989;87(Suppl 5A):274S-277S.
20. Smith G, Leyland M, Farrell I, et al. A clinical, microbiological and pharmacokinetic study of ciprofloxacin plus vancomycin as initial therapy of febrile episodes in neutropenic patients. J Antimicrob Chemother 1988;21:647-55.
21. Talcott J, Finberg R, Mayer R, et al. The medical course of cancer patients with fever and neutropenia. Arch Intern Med 1988;148:2561-8.
22. Talcott J, Siegel R, Finberg R, et al. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10:316-22.
23. Rubenstein E, Rolston K, Benjamin R, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993;71:3640-6.
24. Talcott J, Whalen A, Clark J, et al. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 1994;12:107-14.
25. Griffin T, Buchanan G. Hematologic predictors of bone marrow recovery in neutropenic patients hospitalized for fever: implications for discontinuation of antibiotics and early discharge from the hospital. J Pediatr 1992;121:28-33.
26. Bash R, Katz J, Cash J, et al. Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer 1994;74:189-96.
27. Malik I. Randomized comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet 1992;339:1092-6.
28. Malik I, Khan W, Karim M, et al. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med 1995;98:224-31.
29. Schaad U, Salem MA, Aujard Y, et al. Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. Pediatr Infect Dis J 1995;14:1-9.